Fresenius SE & Co. KGaA

FRE

DE0005785604

Healthcare Facilities & Services

Real-time Estimate Tradegate Other stock markets 10:32:02 2024-07-17 EDT			5-day change	1st Jan Change
30.16 ^EUR	+2.05%		+4.07%	+7.55%

07-16	Fresenius rises - Deutsche Bank: higher annual targets possible	DP
07-16	AlphaValue/Baader Europe Upgrades Fresenius to Buy, Trims PT	MT

FRESENIUS SE : Barclays reiterates its Buy rating

January 28, 2022 at 11:25 am

In a research note published by Hassan Al-Wakeel, Barclays advises its customers to buy the stock. The target price is lowered from EUR 53 to EUR 51.

Latest news about Fresenius SE & Co. KGaA

Fresenius rises - Deutsche Bank: higher annual targets possible	07-16	DP
AlphaValue/Baader Europe Upgrades Fresenius to Buy, Trims PT	07-16	MT
FRESENIUS SE : Deutsche Bank keeps its Buy rating	07-16	ZD
Frankfurt shares open: Political uncertainty weighs on Dax	07-16	DP
FRESENIUS : Some rays of sun behind the clouds	07-12
Lauterbach promotes controversial hospital reform	06-27	DP
New version of clinic atlas available	06-20	DP
Hospital atlas to be slimmed down	06-19	DP
Clinic atlas to become easier to understand - update in a few days	06-18	DP
NRW hospital association expects cuts due to clinic reform	06-16	DP
Health Minister Lauterbach sees hospital reform on the right track	06-13	DP
FRESENIUS SE : Buy rating from Deutsche Bank	06-11	ZD
Barclays Lifts Fresenius PT, Maintains Overweight Rating	06-06	MT
FRESENIUS SE : Buy rating from Jefferies	06-06	ZD
FRESENIUS : Barclays remains positive after a CMD	06-06	CF
Optimism gives Dax a tailwind	06-06	RE
FRESENIUS SE : JP Morgan gives a Neutral rating	06-05	ZD
Dpa-AFX Overview: COMPANIES from 05.06.2024 - 15:15	06-05	DP
FRESENIUS SE : Berenberg reiterates its Buy rating	06-05	ZD
FRESENIUS SE : Barclays reaffirms its Buy rating	06-05	ZD
Fresenius raises targets for hospital business - shares up	06-05	DP
FRESENIUS SE : Jefferies reaffirms its Buy rating	06-05	ZD
Fresenius raises the bar for hospital subsidiary Helios	06-05	RE
Fresenius driven by higher Helios targets	06-05	DP
FRESENIUS SE : Jefferies gives a Buy rating	06-05	ZD

Fresenius SE & Co. KGaA specializes in designing, producing, and selling medical drugs, equipment, and devices used in clinical hospitalization and at home. Net sales break down by activity as follows: - hospital administration and engineering (64.3%; Fresenius Vamed and Fresenius Helios): management of technical facilities and medical equipment, hospital management, design and production of medical equipment for the pharmaceutical sector, etc.; - perfusion and clinical nutrition (35.7%; Fresenius Kabi): sales of parenteral and oral nutrition products, perfusion and vascular filling equipment, transfusion materials, generic injectable products, home medical assistance services in the areas of perfusion, nutrition, and oxygen therapy, etc. Net sales are distributed geographically as follows: Europe (72.4%), North America (12.3%), Asia/Pacific (7.3%), Latin America (6.4%) and Africa (1.6%).

Sector

Healthcare Facilities & Services

Calendar

2024-07-30 - Q2 2024 Earnings Call

Related indices

STOXX EUROPE 600 (EUR) , DAX

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

FRESENIUS : Some rays of sun behind the clouds

July 12, 2024 at 10:44 am

More Strategies

Ratings for Fresenius SE & Co. KGaA

Trading Rating

Investor Rating

ESG Refinitiv

A-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

29.56 EUR

Average target price

37.54 EUR

Spread / Average Target

+27.00%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Healthcare Facilities & Services

	1st Jan change	Capi.
FRESENIUS SE & CO. KGAA	+7.55%	18.12B
HCA HEALTHCARE, INC.	+21.98%	83.53B
CVS HEALTH CORPORATION	-21.56%	75.4B
DR. SULAIMAN AL HABIB MEDICAL SERVICES GROUP COMPANY	+2.32%	26.73B
LABCORP HOLDINGS INC.	-3.53%	18.25B
QUEST DIAGNOSTICS INCORPORATED	+8.96%	16.51B
NATERA, INC.	+78.83%	14.05B
TENET HEALTHCARE CORPORATION	+78.97%	13.03B
PURE HEALTH HOLDING	-27.89%	12.67B
UNIVERSAL HEALTH SERVICES, INC.	+24.13%	12.31B

Other Healthcare Facilities & Services

Fresenius SE & Co. KGaA

Equities

FRE

DE0005785604

Healthcare Facilities & Services

FRESENIUS SE : Barclays reiterates its Buy rating

Latest news about Fresenius SE & Co. KGaA

Chart Fresenius SE & Co. KGaA

Company Profile

Income Statement Evolution

Analysis / Opinion

Ratings for Fresenius SE & Co. KGaA

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Healthcare Facilities & Services